US 12,466,818 B2
Thienyl-aniline compounds for treatment of dermal disorders
John Kincaid, Boston, MA (US); and Matthew Duncton, Boston, MA (US)
Assigned to NFlection Therapeutics, Inc., Boston, MA (US)
Appl. No. 17/294,779
Filed by NFlection Therapeutics, Inc., Boston, MA (US)
PCT Filed Nov. 20, 2019, PCT No. PCT/US2019/000067
§ 371(c)(1), (2) Date May 18, 2021,
PCT Pub. No. WO2020/106305, PCT Pub. Date May 28, 2020.
Claims priority of provisional application 62/769,832, filed on Nov. 20, 2018.
Prior Publication US 2022/0204486 A1, Jun. 30, 2022
Int. Cl. C07D 409/06 (2006.01); A61P 17/00 (2006.01); C07D 333/38 (2006.01); C07D 333/68 (2006.01); C07D 409/12 (2006.01); C07D 413/06 (2006.01)
CPC C07D 409/06 (2013.01) [A61P 17/00 (2018.01); C07D 333/38 (2013.01); C07D 333/68 (2013.01); C07D 409/12 (2013.01); C07D 413/06 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A compound of Formula (Ic) or (Ie-1):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is —N(OR5b)R5a;
R2 is halo;
R2a is halo;
R3a is C1-C6 alkyl;
R5b is C3-C8 cycloalkyl-C1-C6 alkyl, C1-C6 hydroxyalkyl, or amino-C1-C6 alkyl;
R5a is hydrogen;
R6 is C1-C6 alkyl; and
each R9 is independently C1-C6 alkyl.